Danaher Corporation has announced the acquisition of medical diagnostics company Cepheid, strengthening their presence in the Molecular Diagnostics market. Danaher will pay $53 per share in cash, a premium of
2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience
In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture
Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks
